3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
17
Gastrointestinal
8
Thoracic
7
Lymphoid
7
Other hematologic neoplasm
6
Genitourinary
6
Tumor-Agnostic
5
Gynecologic
3
Other
2
Head & Neck
2
Dermatologic
2
CNS
2
Plasma cell
1
Myeloid
1
Classical hematology
1
Conditions
Myelodysplastic Syndromes
1
Cytopenia
1
Interventions
venetoclax
33
fludarabine
32
Cyclophosphamide
31
Azacitidine
29
Specimen Handling
27
Biopsy
19
Cytarabine
18
fludarabine phosphate
15
Whole-Body Irradiation
15
Stem Cell Transplantation
15
Decitabine
15
ruxolitinib
14
Tacrolimus
14
Melphalan
14
Busulfan
14
Mycophenolic Acid
13
asciminib
10
Injections
10
decitabine and cedazuridine drug combination
8
Thiotepa
8
Methotrexate
8
Hematopoietic Stem Cell Transplantation
8
X-Rays
7
Granulocyte Colony-Stimulating Factor
7
Magnetic Resonance Spectroscopy
6
Idarubicin
6
Filgrastim
6
Cyclosporine
6
Blood Specimen Collection
6
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Exercise
×
Myeloid
×
Clear all
NCT06773871
2025-08-19
HemEx
Rigshospitalet, Denmark
Phase NA
Recruiting
36 enrolled